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Page 1 Figure 1 . A surfing analogy as a graphical explanation of how anesthesiologists use a combination of three approaches to administer anesthetics to maintain the anesthetic effect while making rapid recovery possible. Anesthesiologists target the upper portion of the "steep" part of the concentration-effect relationship so that small decreases in concentration translate into large decrements in drug effect at the end of the anesthetic; this can be visualized as a surfer riding the crest of a wave (see text for complete explanation); from Egan and Shafer. 1 Over the last several decades we have witnessed dramatic advances in the scientific underpinnings of intravenous anesthesia. Having been rapidly translated into the clinical domain, the ultimate result of these advances is that total intravenous anesthesia (TIVA), once an impractical fantasy, is now an appealing, workable alternative to the traditional practice of inhalation anesthesia.
This refresher course summary is intended to provide a broad overview of recent advances in the scientific foundation of intravenous anesthetic pharmacology. Drawing upon a "surfing" analogy as a theoretical framework, we will briefly review advances in pharmacokinetics and pharmacodynamics, developments in pharmaceutics such as designer drugs, and improvements in intravenous drug delivery technology.
THE "SURFING ANALOGY" IN ANESTHESIA DRUG SELECTION AND ADMINISTRATION
Anesthesia and reanimation necessitate a standard of precision and accuracy in drug administration not required in most areas of clinical medicine. Anesthetists profoundly depress the central nervous system to maintain the anesthetized state but then must rapidly reanimate the patient after the operation is complete. Although empirically over-dosing every patient is one approach to assuring the patient is adequately anesthetized, it comes at the cost of slow emergence from anesthesia and hemodynamic depression, among others. Anesthetists must therefore target drug levels that are within a relatively narrow therapeutic window to achieve the competing clinical imperatives of adequate anesthesia (without toxicity) and rapid emergence. This "on-off" imperative is unique to anesthesia pharmacology.
A surfing analogy is helpful in conceptualizing the approaches that can be applied to the problem of rational drug administration in anesthesia. 1 The anesthesiologist typically targets the upper portion of the steep part of the concentration-effect relationship; that is, the anesthesiologist targets a concentration that produces considerable drug effect but from which drug effect will recover quickly once drug administration is terminated. This can be visualized as a surfer riding near the crest of a wave as in Figure 1 . Targeting ("surfing") the steep portion of the concentrationeffect relationship makes it possible to achieve large reductions in effect with relatively small decreases in concentration.
There are essentially three approaches to targeting this area of the concentration-effect relationship. Perhaps chief among them is the pharmacodynamic approach, wherein a drug effect measure is employed as a feedback mechanism to guide drug administration. Propofol titrated to a specific processed electroencephalogram target or a muscle relaxant administered to maintain a specific degree of twitch depression as measured by a peripheral nerve stimulator are examples of this pharmacodynamic approach.
Another common approach in targeting the steep portion of the concentration-effect relationship is the pharmacokinetic approach. Drawing upon knowledge about the concentration-effect relationship (i.e., therapeutic windows), the pharmacokinetic approach targets specific drug concentrations that are known to be appropriate for a given anesthetic application. The use of an agent specific vaporizer to deliver some multiple of the agent's minimal alveolar concentration (MAC) and the use of a target controlled infusion device to infuse propofol to a specified concentration (e.g., the Diprifusor ® ) are sophisticated examples of this approach. Of course even in situations where an advanced delivery technology is not employed, standard dosage regimens are devised to achieve concentrations that are within the drug's therapeutic window based on the drug's pharmacokinetic behavior.
A third approach to targeting the steep portion of the concentration-effect relationship can be referred to as the "forgiving drug" or "pharmaceutical" approach. The pharmaceutic approach takes advantage of the responsive pharmacokinetic profiles of modern anesthetic agents. With this approach, within the constraints of acceptable adverse effects such as hemodynamic depression, it is unnecessary to hit the target with as much precision and accuracy as with the other approaches. Because short acting agent concentrations can be manipulated up or down rapidly, adjustments can be made quickly as suggested by pharmacodynamic feedback. If the empirical dosage scheme is obviously too aggressive or too conservative, the anesthetist can achieve a more appropriate level of drug effect in short order.
As a practical matter, of course, anesthetists combine all three approaches (e.g., the pharmacodynamic, pharmacokinetic and pharmaceutic approaches). Increasingly, pharmacokinetically responsive agents are administered by advanced, target controlled delivery devices according to pharmacodynamic feedback. Adjusting the Diprifusor ® propofol target based on feedback from the Bispectral Index Scale ® monitor is an example of this combined approach to anesthesia drug delivery. The scientific advances supporting this three pronged approach to rational drug selection and administration for intravenous anesthesia is the focus of this review.
PHARMACOKINETIC AND PHARMACODYNAMIC ADVANCES The Importance of Covariate Effects: the Example of Hemorrhagic Shock
Easily measured patient characteristics (covariates) such as age and weight are well known to influence the disposition and effect of intravenous anesthetics. Information regarding hemorrhagic shock as a significant covariate impacting intravenous anesthetic pharmacology has recently solidified.
From the earliest days of intravenous anesthesia, anesthetists recognized the need to reduce the dose of intravenous anesthetics during shock. Dr. Halford's famous observation (i.e., that intravenous anesthetics "are an ideal form of euthanasia") in the aftermath of the attack on Pearl Harbor is a sobering, historical example of this firmly entrenched clinical dogma.
2 Although the number of deaths has almost certainly been exaggerated, 3 it is widely believed that the hemodynamic depression associated with thiopentone anesthetic induction in US Naval hospitals at Pearl Harbor contributed to combat related deaths after the attack.
Hemorrhagic shock results in a major redistribution of blood flow within the body. As blood volume decreases, blood flow is increasingly redistributed to the heart, brain and other core organs such as the liver and kidney. Inevitably, blood flow to the metabolic organs (i.e., the liver and kidney) also decreases. From a pharmacologic perspective, the net result of these shock related changes in blood flow is that volume of distribution and clearance will decrease. In terms of drug concentration, this translates into higher drug levels for any given dosage scheme. Figure 2 illustrates the higher mean fentanyl concentrations observed in shocked animals after a brief fentanyl infusion in a bovine isobaric hemorrhage model. 4 The concentrations are approximately double in the shock cohort. Similar increases in concentration have been observed during shock for a variety of intravenous anesthetics, including propofol, etomidate, morphine and remifentanil.
5-10 Interestingly, the altered pharmacokinetics during shock are particularly relevant to propofol, perhaps in part because propofol also exhibits a change in potency that further augments the clinical effect of the increased drug levels. In fact, a propofol infusion regimen that causes typical therapeutic effect in control animals is uniformly lethal when given to animals in shock.
5
Shock can also alter the concentration-effect relationship (i.e., dynamics), although pharmacodynamic alterations are more variable than the changes observed with intravenous drug pharmacokinetics. For example, propofol is more potent in shock versus control animals; that is, the concentration that produces 50% of maximal effect is significantly lower in shocked animals.
In contrast, investigators have not observed significant increases in etomidate's potency during shock, although the data certainly suggest a trend toward increasing potency (the studies may simply have been under-powered).
6,7 Like the case of etomidate, similar data exist for the analgesics morphine and remifentanil (i.e., no obvious change in potency, but a trend toward higher potency). 8, 9 In clinical practice, patients in shock are rarely taken to the operating room for anesthesia and surgery without at least some degree of crystalloid or blood product resuscitation. Using an isobaric hemorrhage method in pigs, Johnson et al studied the effect of aggressive crystalloid resuscitation on the clinical pharmacology of propofol after an episode of severe shock.
11 For propofol, the pharmacokinetic alterations produced by hemorrhage are largely reversed with resuscitation, but the pharmacodynamic alterations (i.e., the increased potency) persist even after fluid resuscitation. Whether these findings can be generalized to other intravenous anesthetic drugs is unknown, but it is likely that similar results would be observed.
It is important to emphasize that the vast majority of this knowledge regarding shock and intravenous anesthetic clinical pharmacology has come from animal investigations because of obvious ethical considerations. However, human data in the form of case reports appear to confirm the animal findings.
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The shock associated modifications in drug behavior mandate dramatic changes in dosing strategy to produce the same degree of drug effect. In a recent editorial by Shafer entitled Shock Values, the dosage reduction required during serious hemorrhagic shock to produce an equivalent degree of drug effect as compared to normal subjects for a variety of intravenous anesthetic drugs (based on animal data) was about 50%. 13 Shock has now been confirmed as an important factor influencing the disposition and effect of intravenous anesthetic drugs.
The Importance of Pharmacodynamic Drug Interactions and Synergy
In anesthesiology, unlike most medical disciplines, pharmacodynamic drug interactions are frequently produced by design. Anesthesiologists take advantage of the pharmacodynamic synergy that results when two drugs with different mechanisms of action but similar therapeutic effects are combined. These synergistic combinations can be advantageous because the therapeutic goals of the anesthetic can often be achieved with less toxicity and faster recovery than when the individual drugs are used alone in higher doses. In fact, except for specific, limited clinical circumstances wherein a volatile agent or propofol alone are acceptable approaches (e.g., a brief operation in a pediatric patient such as tympanostomy tubes), modern day anesthesia is at least a two drug process consisting of an analgesic Figure 3 . An example of the interaction between propofol and opioids. The left panel depicts the plasma alfentanil effective concentration (EC 50 ) versus blood propofol concentration associated with a 50% probability of no response to intraabdominal surgical stimuli, illustrating substantial pharmacodynamic synergy between the two drug classes. The right panel is a computer simulation of the effect site propofol and alfentanil concentrations versus time during the first 40 minutes after termination of target-controlled infusions of the two drugs to levels associated with a 50% probability of no response to surgical stimuli; the bold line superimposed on the concentration decay curves represents the concentration at which 50% of subjects are predicted to regain consciousness. The bold line parabolic minimum (marked by the arrow) is the concentration target pair that produces equivalent pharmacodynamic synergy but more rapid recovery. The right panel is thus a clinically useful integration of druginteraction pharmacodynamic data with pharmacokinetic information, permitting the rational selection of propofol-alfentanil targets (i.e., hypnotic-opioid ratios); from Vuyk et al. [16] [17] [18] (typically an opioid) and an hypnotic agent. Therefore, from a strictly pharmacological perspective, anesthesiology is the practice of pharmacologic synergism using central nervous system depressants.
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Propofol-opioid interactions are characterized using "EC 50 " reduction study methodology with a clinical effect measure such as hemodynamic or movement response to surgical stimuli. Like MAC reduction studies, propofol-opioid interaction studies exhibit a general pattern irrespective of the opioid that is used. Opioids produce a marked reduction in the level of propofol required; as the opioid concentration increases, the propofol requirement decreases asymptotically toward a non-zero minimum.
The left panel of Figure 3 shows the propofol and alfentanil concentrations necessary to prevent hemodynamic or movement response to intra-abdominal surgical stimuli in 50% of patients as reported by the pioneering work of Vuyk et al. 16 This graph is typical of all propofol-opioid pharmacodynamic interactions no matter which effect is being studied. 17 Low concentrations of alfentanil dramatically reduce the need for propofol, but even very high concentrations of alfentanil cannot completely eliminate the need for propofol to maintain adequate anesthesia. The relationship is highly non-linear, meaning that the dosage reduction of one drug produced by an increase in the other is not simply proportional, demonstrating the substantial pharmacodynamic synergy of the drug combination. Experiments like these suggest that at high propofol concentrations, low dose alfentanil is contributing primarily an analgesic effect to the overall anesthetized state, whereas at lower propofol concentrations, the higher alfentanil concentration required is also contributing importantly to the hypnotic effect.
16
EC 50 reduction studies form the basis of our clinical understanding of the propofol-opioid interaction. The right panel of Figure 3 is a computer simulation of effect site propofol and alfentanil concentrations versus time during the first 40 minutes after termination of 300 minute computer controlled infusions targeted to concentrations designed to achieve a 50% probability of no response to surgical stimulation. 18 Based on isobolographic drug interaction analysis, this simulation enables the rational selection of concentration target pairs for propofol and alfentanil (and other opioids as well). The bold line superimposed on the concentration decay curves represents the concentration at which 50% of subjects are predicted to regain consciousness. The bold line is a parabolic curve identifying the concentration pair that optimizes predicted recovery time. According to the simulation, the concentration targets for propofol and alfentanil to minimize the time to return of consciousness after a 300 minute infusion while maintaining a 50% probability of no response to surgical stimuli intraoperatively are 3.4 mcg/ml and 88.9 ng/ml respectively. 18 The appropriate targets can be computed for any opioid, for any length infusion and for any percentage probability of non-response. Designing dosage regimens to hit these targets using pharmacokinetic models from the literature is a simple exercise. 17 The clinical application of these drug interaction models through the use of computer simulation constitutes a revolutionary advance in our understanding of intravenous anesthetic clinical behavior.
The rational selection of the appropriate propofol-opioid ratio is in large part a function of opioid pharmacokinetics. Because the fentanyl congeners can be viewed as pharmacodynamic equals with important pharmacokinetic differences, the time to return of consciousness depends predominantly on the selected opioid (and also on the duration of infusion). 17, 19 For the longer acting fentanyl congeners (i.e., alfentanil, sufentanil and fentanyl), a lower opioid concentration target and a higher propofol concentration target is prudent because the opioid pharmacokinetics are the rate limiting step in the recovery process. When the short acting opioid remifentanil is combined with propofol, on the other hand, a lower propofol concentration is targeted because propofol's pharmacokinetic profile is the primary determinant of the time to regaining consciousness. 17 Of course pharmacodynamic considerations also come into play when selecting the appropriate propofol-opioid ratio. In the hemodynamically compromised patient, for example, a higher opioid concentration target might help to promote hemodynamic stability. In patients prone to nausea and vomiting after receiving opioids, a higher propofol concentration target might be prudent.
It is important to note that simple isobolographic drug interaction analysis approaches (as illustrated in Figure 3 ) are being supplanted by "response surface" drug interaction analysis methods.
14,20,21 An isobologram is only a single "slice" through a much larger drug interaction "surface." The isobologram shown in the left panel of Figure 3 , therefore, represents only a small fraction of the overall interaction. Response surfaces, on the other hand, characterize the drug interaction over the entire spectrum of drug concentration and effect.
The substantial opioid-hypnotic synergy demonstrated by Vuyk et al with isobolographic analysis methods 22 has been confirmed for propofol and remifentanil using response surface analysis approaches with surrogate drug effect measures gathered in volunteers. 23, 24 Studies conducted in volunteers with surrogate effect measures (i.e., pressure/electrical pain, sedation scores, among others) provide a unique opportunity to describe the entire range of a two drug interaction, from very low concentrations of the first agent and very high concentrations of the second and vice versa over the entire spectrum of clinically relevant concentrations. It would be difficult to gather such data in patients because one cannot deliberately produce inadequate anesthesia in patients whereas this is possible in the volunteer setting using non-invasive, experimental pain measurements.
PHARMACEUTICAL CONSIDERATIONS Remifentanil: a Prototype Designer Drug
Remifentanil is a prototype example of how specific clinical goals can be achieved by designing molecules with specialized structure-activity (or structure-metabolism) relationships. The medicinal chemists responsible for the development of remifentanil sought to produce a potent opioid that would lose its mu receptor agonist activity upon ester hydrolysis, thereby creating an intravenous opioid with a very short acting pharmacokinetic profile. 25 The perceived unmet need driving remifentanil's development was that the practice of anesthesia requires a degree of pharmacokinetic responsiveness unnecessary in most medical disciplines and that anesthetics (opioids included) therefore ought to be Figure 5 . A schematic representation of a target controlled infusion (TCI) system for anesthetic drugs. Based on knowledge of therapeutic windows, patient response and the current prediction of drug concentration (Cpredicted), the physician sets the anesthetic drug concentration target. Using a pharmacokinetic model for the drug, the computer computes the appropriate infusion rates over time to achieve and maintain the target concentration and directs the infusion pump to administer the appropriate dose (see text for details); From Egan.
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short acting so that they can be titrated up and down as necessary to meet the dynamic needs of the patient during the rapidly changing conditions of anesthesia and surgery.
Compared to the currently marketed fentanyl congeners, remifentanil's context sensitive halftime is short, on the order of about 5 minutes. 26 Pharmacodynamically, remifentanil exhibits a short latency to peak effect similar to alfentanil and a potency slightly less than fentanyl.
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Although remifentanil's role in modern anesthesia practice is still evolving, its unique pharmacokinetic profile certainly makes it possible to manipulate rapidly the degree of opioid effect in a way that could not be achieved with the previously marketed fentanyl congeners. Remifentanil is therefore perhaps best suited for cases where its responsive pharmacokinetic profile can be exploited to advantage (e.g., when rapid recovery is desirable, when the anesthetic requirement rapidly fluctuates, when opioid titration is unpredictable or difficult, when there is a substantial danger to opioid overdose, or when a "high dose" opioid technique is advantageous but the patient is not going to be mechanically ventilated postoperatively).
28

TECHNOLOGICAL ADVANCES Computerized Drug Delivery Methods
Until recently, the most sophisticated delivery device for the administration of opioids was the calculator pump, a device that enabled an accurate and precise delivery of fluid per unit of time. Used in both clinical and research settings, the physician operator of these devices simply specifies a delivery rate in terms of mg/hr or mcg/kg/min, etc. The patient controlled analgesia machine is a hybrid of the calculator pump that permits patient control of opioid administration within physician constrained parameters. The primary limitation of these calculator pumps is that they do not achieve the pharmacokinetic exactness possible with more advanced methods of administration.
Advances in pharmacologic modeling and infusion pump technology have now made it possible to administer injectable anesthetics via a computer controlled infusion pump. 29 By coding a pharmacokinetic model into a computer program and linking it to an electronic pump modified to accept computerized commands, delivery according to a drug's specific pharmacokinetic parameters can be achieved. The physician operating a target controlled infusion (TCI) system designates a target concentration to achieve rather than specifying an infusion rate. The TCI system then calculates the necessary infusion rates to achieve the targeted concentration as shown in Figure 5 . 30 Borrowing from inhalation anesthesia concepts, TCI pumps make progress toward the concept of a "vaporizer" for intravenous drugs because they address the fundamental limitation associated with delivering drugs directly into the circulation. Constant rate infusions result in continuous drug uptake. TCI systems, in contrast, gradually decrease the rate of infusion based on the drug's pharmacokinetics. Known in its general form as the BET method (i.e., bolus, elimination and transfer), 31 the dosing scheme determined by a TCI pump accounts for the initial concentration after a bolus dose and the subsequent drug distribution and clearance while an infusion is ongoing.
Delivery of drug via a TCI system requires a different knowledge base of the physician. Rather than setting an infusion rate based on clinical experience and literature recommendations, the physician using a TCI system designates a target concentration and the system calculates the infusion rates necessary to achieve the concentration over time. The TCI system changes the infusion rates at frequent intervals (i.e., as often as every 10 seconds). Successful use of a TCI pump thus requires knowledge of the therapeutic concentrations appropriate for the specific clinical application. 29 Computer controlled drug delivery in the operating room is an exciting area with promising potential. 32 Sadly, although TCI systems are widely used in North America for research purposes, they are not yet commercially available for routine clinical use (unlike much of the rest of the world). 1 
Clinical Pharmacology Graphical Display Systems
Although PK-PD models can theoretically be used to predict the time course of drug concentration and effect for any conceivable dosage scheme (if the models are available…), the mathematical complexity of these models has precluded their practical introduction into the operating room in real time. Thus, PK-PD models characterizing anesthetic drug behavior have primarily been used as a computer simulation research tool to gain insight into how anesthetics can be rationally selected and administered.
Research is now being conducted to bring anesthetic pharmacology models to the operating room through automatic acquisition of the drug administration scheme and real time display of the predicted pharmacokinetics and pharmacodynamics. [33] [34] [35] Based on high resolution PK-PD models, including a model of the PD synergy between opioids and propofol, this technology automatically acquires the drug doses administered by the clinician and shows the drug dosing history (bolus doses and infusion rates), the predicted drug concentrations at the site of action (past, present and future) and the predicted drug effects including sedation, analgesia and neuromuscular blockade.
Although it is too early to predict what role this technology may play in determining a rational anesthetic dosage strategy, preliminary evidence suggests that it might be well received by clinicians. It is conceivable that in the future a real-time display of the predicted pharmacokinetics and pharmacodynamics of anesthetic drugs might be found alongside the traditional physiologic vital sign monitors.
